Tag:
Amgen
Latest Headlines
Latest Headlines
Biomarkers rescue Amgen's MAb, support Roche's Avastin
Studies give boost to Genentech/Roche's ($RHHBY) Avastin (bevacizumab) and Amgen's ($AMGN) rilotumumab.
The biggest R&D spenders in biotech
Last year the top 10 biotechs in the world spent $10.2 billion on R&D, up a whopping 13% over their $8.9 billion track record in 2010.
PRA expands European ops with new Dutch and British offices
PRA will open two new offices in Europe to support its growing staff and capabilities.
Amgen pushes agenda for biosimilars on the FDA
The Thousand Oaks, CA-base drugmaker is one of 30 organizations on the docket today for the FDA's informal stakeholder meeting to discuss regulation of biosimilars.
Amgen, VC groups pump $16.5M into Sutro Biopharma
Skyline Ventures led the second $16.5 million closing of the San Francisco-based startup's Series C round, which included backing from Amgen Ventures, Lilly Ventures, Alta Partners and SV Life Sciences.
Pharma continues parachute-building for patent cliff
Last month was a big one for pharma dealmaking, as anyone following the industry well knows. The list of deals, bids and potential deals is long--$33 billion long.
Amgen gets a no from the FDA on extended use of Xgeva
The FDA told Amgen no to an expanded use of its cancer treatment Xgeva, one of the company's most important drugs, saying the company could try again with more data.
Amgen putting $200M into plant it bought from Pfizer
About 100 new jobs will be needed when the project is complete late next year.
PRA snags Amgen's PhIII biosimilars contract
The contracting coup comes four months after Amgen tied up with Watson on an ambitious pact to develop biosimilars of some leading cancer therapies.
PRA grabs global biosimilar research pact with Amgen
The contracting coup comes four months after Amgen ($AMGN) tied up with Watson ($WPI) on an ambitious pact to develop biosimilars of some leading cancer therapies.
